The Medical Affairs Summit, scheduled for 24 – 25 October at the prestigious Encore Boston Harbor, in Boston, MA, is an exclusive, invitation-only summit that will bring together Clinical Trial Executives Representing Americas Pharmaceutical Industries and Innovative Pharmaceutical Companies from Across North America.
The summit’s content is aligned with key medical affairs challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.
This year’s speaker lineup includes:
- Victoria Samonte, M.D., Director, Medical Affairs, Abbott
- Giovanni Passiatore, Head North America Medical Affairs, Chiesi Global Rare Diseases
- Donnie Wooten, Head, Global Field Medical Excellence & Omnichannel Engagements, Organon & Co.
- Mansi Jamindar, Medical Director, Oncology, Daiichi Sankyo, Inc.
For more information about the Medical Affairs Summit, please contact Anna Iacovou at annai@marcusevanscy.com or visit us here.
Related Content
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
In this webinar, Dr. Joseph Zabinski discusses the digital phenotyping process and several concrete applications to demonstrate how AI can add value to analyses of the patient journey across the life sciences spectrum.
Clinical Trial Innovation: How Healthcare Technology is Evolving
Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.
Keeping pace with the evolving global landscape in vaccine development
Hear from a panel of Life Science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space. What has been COVID-19's impact on drug development and the regulatory landscape? Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage. Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.